Lithium in Drinking Water Linked to Dementia Incidence

Share this content:
Lithium in Drinking Water Linked to Dementia Incidence
Lithium in Drinking Water Linked to Dementia Incidence

FRIDAY, Aug. 25, 2017 (HealthDay News) -- Lithium in drinking water is associated with the incidence of dementia in a nonlinear pattern, according to a study published online Aug. 23 in JAMA Psychiatry.

Lars Vedel Kessing, M.D., from the University of Copenhagen in Denmark, and colleagues conducted a population-based study to examine whether the incidence of dementia in the general population covaries with long-term exposure to microlevels of lithium in the drinking water. Data were included for 73,731 patients with dementia and 733,653 controls.

The researchers observed a significant difference in lithium exposure for patients with a diagnosis of dementia (median, 11.5 µg/L) and controls (median, 12.2 µg/L; P < 0.001). The association was nonlinear. The incidence rate ratio (IRR) of dementia was decreased in those exposed to more than 15.0 µg/L (IRR, 0.83; 95 percent confidence interval, 0.81 to 0.85; P < 0.001) and 10.1 to 15.0 µg/L (IRR, 0.98; 95 percent confidence interval, 0.96 to 1.01; P = 0.17), and increased with exposure to 5.1 to 10.0 µg/L (IRR, 1.22; 95 percent confidence interval, 1.19 to 1.25; P < 0.001), compared with those exposed to 2.0 to 5.0 µg/L. With Alzheimer's disease and vascular dementia as outcomes, the patterns were similar.

"Long-term increased lithium exposure in drinking water may be associated with a lower incidence of dementia in a nonlinear way; however, confounding from other factors associated with municipality of residence cannot be excluded," the authors write.

One author disclosed financial ties to the pharmaceutical industry.

Abstract/Full Text
Editorial

Share this content:

is free, fast, and customized just for you!

Already a member?

Sign In Now »

Drug Lookup

Browse drugs by: BrandGenericDisease

Trending Activities

All Professions


Sign up for myCME e-newsletters


More in Home

FDA OKs Nucala for Eosinophilic Granulomatosis With Polyangiitis

FDA OKs Nucala for Eosinophilic Granulomatosis With Polyangiitis

First drug to be approved for rare autoimmune disease that leads to vasculitis

Findings Support Individualized Glycemic Control in T2DM

Findings Support Individualized Glycemic Control in T2DM

Approach saved $13,547/patient vs uniform intensive control, with lower medication costs

Atherosclerosis ID'd in Many Without CV Risk Factors

Atherosclerosis ID'd in Many Without CV Risk Factors

LDL-C independently associated with the presence and extent of atherosclerosis

is free, fast, and customized just for you!

Already a member?

Sign In Now »